DGAP-News: ALACRIS RECEIVES GERMAN INNOVATION AWARD 2015


DGAP-News: Alacris Theranostics GmbH / Key word(s):
Miscellaneous/Miscellaneous
ALACRIS RECEIVES GERMAN INNOVATION AWARD 2015

28.04.2015 / 13:30

---------------------------------------------------------------------

Press Release 

______________________________________________________________

ALACRIS RECEIVES GERMAN INNOVATION AWARD 2015
______________________________________________________________

Berlin, 28th April 2015 - Alacris Theranostics GmbH announced today that
they have been awarded the highly renowned German Innovation Award 2015.

Alacris Theranostics received the award in the category Medium-Sized
Enterprises for ModCellTM, an innovative system biology-based modelling
approach for personalised diagnostics, therapy and drug stratification with
an initial focus on cancer. ModCellTM can predict potential effects and
side effects of treatments on the basis of a detailed molecular analysis of
the patient's tumor to support physicians in their decision making for an
optimized therapy for each individual patient (currently in a clinical
trial). In addition, ModCellTM can be used in both, biomarker
identification and for the development and repositioning of drugs. By
simulating drug activity in "virtual clinical trials", ModCellTM allows for
a faster, more efficient drug development and approval process.

The unique feature of ModCellTM is the use of a systems biology model in
the field of personalised medicine which is significantly different from
statistical, correlative approaches, in most cases based only on single or
multiple biomarkers. The analysis of individual biomarkers allows only
examination of a partial aspect of the disease. ModCellTM however,
generates a computer model of a "virtual patient" on the basis of analysing
the totality of the biological data and therefore helps to identify
individualised, promising treatment strategies for cancer patients.

"We are delighted that the jury of the German Innovation Award has honoured
our innovative ModCellTM modelling approach," commented Bodo Lange, PhD,
CEO of Alacris Theranostics GmbH. "The award is an important recognition of
our approach and our work. This prize further encourages us to continuously
develop and improve ModCellTM for achieving the best possible treatment for
patients in the fight against cancer."

Alacris has established its own state-of-the-art Next Generation Sequencing
Laboratory in Berlin with the appropriate sequencing and data analysis
capabilities in order to generate data for the modelling of patients and
tumours. With the development and commercialisation of this innovation in
personalised healthcare, Alacris also attracts highly qualified
international young scientists to the Berlin area. Berlin plays an
important role as an attractive location for researchers, companies,
founders and consequently investors.

About German Innovation Award 
In 2010, Accenture, EnBW, Evonik and Wirtschaftswoche jointly formed the
initiative "The German Innovation Award" to reward German companies with
outstanding, pioneering innovations that have the potential to change
business and markets. The prize is awarded in three categories to large
companies, medium sized enterprises and start-ups. In addition to product
innovations and innovative business models, the jury also considered
processes, services and outstanding organisational and marketing
innovations.

About Alacris Theranostics GmbH
Berlin-based Alacris Theranostics (www.alacris.de), a spin-off from the Max
Planck Institute for Molecular Genetics, develops new approaches in
personalised medicine for cancer patient diagnosis, treatment and drug
stratification. The Company is applying the systems biology approach
ModCellTM to provide a "Virtual Patient" model based on genome and
transcriptome information obtained by next generation sequencing, mutation
and drug databases as well as complex pathway information. This "Virtual
Patient" model can predict the effects of drug treatment and optimised
combinatory treatments to provide the means for truly personalised medicine
approaches. In addition, Alacris' "Virtual Clinical Trials" system enables
the in silico analysis of drugs, thus identifying stratified patient groups
with particular genetic and molecular profiles that could be targeted by a
drug to allow more efficient drug development and approval.
# # #

 
Contact: 

Alacris Theranostics GmbH 
Dr Bodo Lange, CEO 
Fabeckstrasse 60-62 
D-14195 Berlin 
Germany 
Phone: + 49 30 8431 22 510 
Email: info@alacris.de 
www.alacris.de

MC Services AG 
Anne Hennecke, Managing Partner 
Tel.: +49 211 529 252 22
Email: anne.hennecke@mc-services.eu



---------------------------------------------------------------------

28.04.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


349739 28.04.2015